Low‐Dose Interleukin‐2 in Patients with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial
The IL-2 immunotherapeutic strategy was safe and well-tolerated. IL-2 q4wks effectively restored Treg populations, leading to modification in inflammatory mediators and AD biomarkers, while also showing promising trends in clinical scales. These findings provide a foundation for further investigation of low-dose IL-2 as a potential treatment for Alzheimer's Disease.
Authors
- Belén Pascual (ORCID: https://orcid.org/0000-0002-4467-7406)
- Joseph C. Masdeu (ORCID: https://orcid.org/0000-0001-9955-6954)
- Alireza Faridar
- Nazaret Gamez (ORCID: https://orcid.org/0000-0001-6847-7735)
- Michael Grundman
- Stanley H Appel
Institutions
- Houston Methodist (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101215
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00